Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Alecensaro | alectinib | ALK-positive NSCLC | Received | |||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Received | |||
| TBC | rozanolixizumab | Generalized myasthenia gravis (gMG). | Pending | |||
| Vanflyta | quizartinib | acute myeloid leukemia (AML) | Pending | |||
| N/A | enzalutamide | Genito-urinary cancer (prostate cancer) | Pending | |||
| Spevigo | spesolimab | generalized pustular psoriasis (GPP) | Pending | |||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
| Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
| Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Pending | |||
| Ferinject | ferric carboxymaltose | Iron deficiency anemia | Pending |
Last Updated : May 2, 2024